Sirtex develops & delivers interventional oncology treatments using novel small particle technology to improve outcomes for patients with metastatic colorectal cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during SIRT. Data has shown a statistically significant improvement of 7.9 months in median PFS in the liver for patients with unresectable mCRC treated first line with SIR-Spheres Y-90, plus standard chemotherapy. Learn more at www.sirtex.com.
300 Unicorn Park Drive
Woburn, Massachusetts 01801